Hyperinsulinemia, hyperglycemia, and impaired hemostasis: The Framingham Offspring Study

JAMA

Volumn 283, Issue 2, 2000, Pages 221-228

  Meigs, James B ^a,b   Mittleman, Murray A ^c   Nathan, David M ^b   Tofler, Geoffrey H ^c   Singer, Daniel E ^b   Murphy Sheehy, Patricia M ^b   Lipinska, Izabela ^c   D'Agostino, Ralph B ^d   Wilson, Peter W F ^b,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY   (United States)

^d USA   (United States)

^e FRAMINGHAM HEART STUDY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD VISCOSITY; BODY MASS; CARDIOVASCULAR RISK; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 0034639491     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.2.221     Document Type: Article

References (78)

1. Morists NJ, Stevens LR, Head J, Fuller JH, Jarrett RJ, Keen H. A prospective study of mortality among midle-aged diabetic patients. Diabetologia. 1990; 33:338-383.
2. UK Prospective Diseases Study Group. UK Prospective Ovaries Study (ORPDS) 17. Ann Intern Med. 1996;1243(pt 2):136-143.
3. Karssel WB, McGee DL. Diabetes and cardiovascular disease. JAMA. 1979;241:2036-2038.
4. Resssis GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1666-1667.
5. Rufina SM, Valdez RA, Hazuda HF, et al. Prospectice analysis of the insulin resistance syndrome (syndrome 8). Diabetes. 1992;41:715-722.
6. Sergy PJ. Cardiovascular complications of diabetes melitus. Ann Intern Med. 1996;1240 pt.23:123-136.
7. Thompson SG, Kienast E, Pyke SD, Hessdale F, van de Los K. Hemostatic factors and the act of myocardial infections or sudden death in patients with angio pectoris. N Engl J Med. 1993;332:833-841.
8. Meade TW, Brozovic M, Chakrabarti RR, et al. Haemostatic function and ischaemic heart disease. Lancet. 1986;2:533-537.
9. Folsom AP, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and assistance for coronary heart disease. Circulation. 1997;39:1102-1108.
10. Juhan-Vague I, Alessi MC, Vague P. Increased plasminogen activator inhibitor 1 levels. Diabetologia. 1983;38:457-462.
11. Schnider DJ, Nordt TK, Sobel BC. Attenuated fibrinolysis and accelerated atherogenesis of type II diabetic patients. Diabetes. 1993;42:1-3.
12. Juhan-Vague I, Thompson SG, Jesperson J. Involvement of the hemostatic system of the insulin resistance syndrome. Arterioscler Thromb. 1993;13: 1865-1873.
13. Elisson M, Asplund K, Evrin PE, Dodard B, Lundblad D. Hyperinsulinemia predicts how tissue plasminogen activity in a healthy population. Metabolism. 1994;33:1579-1586.
14. Cortan MG, Folsom AR, Finch A, et al. Associations of factor VIII and von Willeband factor with age, race, sex, and risk factors for atherosclerosis. Thromb Haemost. 1993;70:380-385.
15. Nagi DK, Mohamed Ali V, Jain SK, Walji S, Yudkin JS. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians. Diabet Med. 1996;13:59-64.
16. McGill JB, Schneider DJ, Arfken CL, et al. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes. 1994;43:104-109.
17. Kannel WB, Feinleib M, McNamara JR, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. Am J Epidemiol. 1979;110:281-290.
18. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183-1197.
19. Cupples LA, D'Agostino RB. Some risk factors related to the annual incidence of cardiovascular disease and death using pooled repeated biennial measurements. In: Kannel W, Wolf P, Garrison R, eds. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Washington, DC: US Dept of Commerce; 1988:sect 34.
20. National Institutes of Health. Health implications of obesity. Ann Intern Med. 1985;103:1073-1077.
21. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157: 2413-2446.
22. Kannel WB, Sorlie P. Some health benefits of physical activity. Arch Intern Med. 1979;139:857-861.
23. Nathan DM. Labile glycosylated hemoglobin contributes to hemoglobin A1 as measured by liquid chromatography or electrophoresis. Clin Chem. 1981;27: 1261-1263.
24. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
25. Declerck PJ, Alessi MC, Verstreken M, Kruithof EKO, Juhan-Vague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood. 1988;71:220-225.
26. Ranby M, Bergsdorf N, Nilsson T, Melbring G, Winblad B, Bucht A. Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme linked immunosorbent assay. Clin Chem. 1986;32:2160-2165.
27. Penny W, Weinstein M, Salzman EW, Ware JA. Correlation of circulating von Willebrand factor levels with cardiovascular hemodynamics. Circulation. 1991;83:1630-1636.
28. Clauss AV. Gerinnungsphysiologische Scnellemethode zur Bestimmung des Fibrinogens. Acta Haematol. 1957;17:237-246.
29. McNamara JR, Schaefer EJ. Automated enzymatic standardized lipid analyses for plasma and lipid lipoprotein fractions. Clin Chim Acta. 1987;166:1-8.
30. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-magnesium precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin Chem. 1982;28:1379-1382.
31. SAS Institute Inc. SAS/STAT User's Guide. 4th ed. Cary, NC: SAS Institute Inc; 1989.
32. Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia, Pa: Lippincott-Raven Publishers; 1998.
33. Despres J-P, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957.
34. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men. Circulation 1998;98:398-404.
35. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988; 318:1315-1321.
36. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996;19:257-267.
37. Knatterud CL, Klimt CR, Levin ME, Jacobsen ME, Goldner MG. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes, VII. JAMA. 1978;240:37-42.
38. Abraira C, Colwell J, Nutall F, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Arch Intern Med. 1997;157: 181-188.
39. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
40. Barrett-Connor E. Does hyperglycemia really cause coronary heart disease? Diabetes Care. 1997;20:1620-1623.
41. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Diabetes. 1987;36:689-692.
42. 1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes. 1992;41:202-208.
43. Stout RW. Insulin and atheroma: a 20-year perspective. Diabetes Care. 1990;13:631-654.
44. Wingard DL, Barrett-Connor EL, Ferrara A. Is insulin really a heart disease risk factor? Diabetes Care. 1995;18:1299-1304
45. Rewers M, D'Agostino RB Jr, Burke G, et al. Coronary artery disease is associated with low insulin sensitivity independent of insulin levels and cardiovascular risk factors. Diabetes. 1996;45(suppl 2):52A.
46. Verheugt FWA, ten Cate JW, Sturk A, et al. Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries. Am J Cardiol. 1987;59:1075-1079.
47. Sobel BE. Increased plasminogen activator inhibitor-1 and vasculopathy: a reconcilable paradox. Circulation. 1999;99:2496-2498.
48. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-126.
49. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940-943.
50. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis. Circulation. 1995;91:284-290.
51. Haffner SM, D'Agostino R, Mykkanen L, et al. Proinsulin and insulin concentrations in relation to carotid wall thickness. Stroke. 1998;29:1498-1503.
52. Vague P, Juhan-Vague I, Aillaud MF, et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism. 1986;35:250-253.
53. Lindahl B, Asplund K, Eliasson M, Evrin PE. Insulin resistance syndrome and fibrinolytic activity. Northern Sweden MONICA Study. Int J Epidemiol. 1996; 25:291-299.
54. Mykkanen L, Ronnemaa T, Marniemi J, et al. Insulin sensitivity is not an independent determinant of plasminogen activator inhibitor-1 activity. Arterioscler Thromb. 1994;14:1264-1271.
55. Asplund-Carlson A, Hamsten A, Wiman B, Carlson LA. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity. Diabetologia. 1993;36:817-825.
56. Cigolini M, Targher G, Seidell JC, et al. Relationships of plasminogen activator inhibitor-1 to anthropometry, serum insulin, triglycerides and adipose tissue fatty acids in healthy men. Atherosclerosis. 1994; 106:139-147.
57. Alessi MC, Peiretti F, Morange P, et al. Production of plasminogen activator inhibitor 1 by human adipose tissue. Diabetes. 1997;46:860-867.
58. Alessi MC, Juhan-Vague I, Kooistra T, et al. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost. 1988;60:491-494.
59. Pandolfi A, Iacoviello L, Capani F, et al. Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture. Diabetologia. 1996;39:1425-1431.
60. Latron Y, Chautan M, Anfosso F, et al. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb. 1991;11:1821-1829.
61. Medvescek M, Keber D, Stegnar M, Borovnicar A. Plasminogen activator inhibitor 1 response to a carbohydrate meal in obese subjects. Fibrinolysis. 1990; 4:89-90.
62. Calles-Escandon J, Mirza SA, Sobel BE, Schneider DJ. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes. 1998;47:290-293.
63. Grant PJ, Kruithof EK, Felley CP, Felber JP, Bachmann F. Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man. Clin Sci. 1990;79:513-516.
64. Vuorinen-Markkola H, Puhakainen I, Yki-Jarvinen H. No evidence for short-term regulation of plasminogen activator inhibitor activity by insulin in man. Thromb Haemost. 1992;67:117-120.
65. Anderson RL, Hamman RF, Savage PJ, et al. Exploration of simple insulin sensitivity measures derived from frequently sampled intravenous glucose tolerance (FSIGT) tests. Am J Epidemiol. 1996;142:724-732.
66. Mykkanen L, Zaccaro DJ, Tracy R, Haffner SM. Relationship of fibrinogen and PAI-1 with insulin sensitivity in normoglycemic subjects. Diabetes. 1997;46 (suppl 1):72A.
67. Meigs JB, D'Agostino RB, Wilson PWF, et al. Risk variable clustering in the insulin resistance syndrome. Diabetes. 1997;46:1594-1600.
68. Yudkin JS, Stehouwer CDA, Emis JJ, Coppack SW. C-reactive protein in healthy subjects. Arterioscl Thromb Vasc Biol. 1999;19:972-978.
69. Pinkney JH, Stehouwer CD, Coppack SW, Yudkin JS. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes. 1997;46(suppl2):S9-S13.
70. Haffner SM, Mykkanen L, Valdez RA, et al. Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome. J Clin Endocrinol Metab. 1994;79:1806-1810.
71. Nordt TK, Schneider DJ, Sobel BE. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. Circulation. 1994; 89:321-330.
72. Fuller JH, Keen H, Jarrett RJ, et al. Haemostatic variables associated with diabetes and its complications. BMJ. 1979;2:964-966.
73. Ganda O, Arkin CF. Hyperfibrinogenemia. Diabetes Care. 1992;15:1245-1250.
74. Missov RM, Stolk RP, van der Bom JG, et al. Plasma fibrinogen in NIDDM: the Rotterdam Study. Diabetes Care. 1996;19:157-159.
75. Eliasson M, Roder ME, Dinesen B, et al. Proinsulin, intact insulin, and fibrinolytic variables and fibrinogen in healthy subjects. Diabetes Care. 1997;20:1252-1255.
76. Mansfield MW, Heywood DM, Grant PJ. Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM. Circulation. 1996;94:2171-2176.
77. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care. 1993;16:621-629.
78. Emanuele N, Azad N, Abraira C, et al. Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins. Arch Intern Med. 1998;158:2485-2490.